LILLY RECEIVES MHRA MARKETING AUTHORISATION IN GREAT BRITAIN FOR TIRZEPATIDE (MOUNJARO ®▼) IN ALTERNATIVE KWIKPEN® PRESENTATION FOR TWO INDICATIONS
BASINGSTOKE, 26th January 2024 – Eli Lilly and Company announced today that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation (MA) for tirzepatide solution for injection in an alternative KwikPen® presentation, for two indications:
- For the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:
- as monotherapy when metformin is considered inappropriate due to intolerance or contraindications
- in addition to other medicinal products for the treatment of diabetes.i
- For weight management, including weight loss and weight maintenance, as an adjunct to a reduced-calorie diet and increased physical activity in adults with an initial BMI of:
- ≥ 30 kg/m2 (obesity) or
- ≥ 27 kg/m2 to < 30kg/m2 (overweight) in the presence of at least one weight-related co-morbidity (e.g. hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes).i
“The MHRA is the first major regulator in the world to issue marketing authorisation for the alternative KwikPen presentation for tirzepatide, demonstrating their clear focus on speeding innovation to help patients. This will enable Lilly to begin supply to the UK within weeks,” said Laura Steele, President and General Manager of UK and Northern Europe at Lilly. “Diabetes and obesity are chronic, long-term conditions with a huge impact on people’s health and quality of life, and Lilly is deeply committed to making people’s lives better in these areas. We recognise there is significant unmet need and also high demand for this class of new medicines – we ask healthcare professionals to ensure all prescribing is within the authorised indications.”
Tirzepatide is a once-weekly GIP (glucose-dependent insulinotropic polypeptide) receptor and GLP-1 (glucagon-like peptide-1) receptor agonist and has previously received marketing authorisation in Great Britain for these two indications in different presentations.
The most common side effects of the medicine are nausea, diarrhoea, vomiting and constipation. Low blood sugar (hypoglycaemia) is also very common in patients with diabetes when used with sulphonylurea or insulin. Symptoms of this can include headache, drowsiness, weakness, dizziness, feeling hungry, confusion, irritability, fast heartbeat and sweating.
Women with obesity or overweight using oral contraceptives should consider also using a barrier method of contraception (e.g., a condom) or switching to a non-oral contraceptive method for 4 weeks after starting tirzepatide and for 4 weeks after each increase in dose.
# # #
About tirzepatide solution for injectioni
Tirzepatide solution for injection activates the body’s receptors for GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1), which are natural incretin hormones responsible for regulating blood glucose levels in response to eating food.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme: website www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
About Lilly
Lilly unites caring with discovery to create medicines that make life better for people around the world. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are advancing new discoveries to solve significant health challenges, in diabetes care, obesity, Alzheimer’s disease, immunology and oncology. To learn more, visit www.lilly.co.uk or follow us on LinkedIn.
References
- Summary of Product Characteristics available from UKMedInfo@lilly.com
